With the development of research, the evidence emerging later also supports this finding
This ensures that communication can be established easily
This leads to dose-dependent weight loss (typically 8-15% in monotherapy trials), with additive effects when combined with GLP-1 agonists like semaglutide due to complementary mechanisms on energy balance and gastrointestinal function
In a report published in November, 2023, based on data collected between 2015 and 2022, an estimated 30% of Canadian adults were classified as obese based on BMI measures (i.e., BMI greater than 30)
custom protocols offer dose-adjustment flexibility but require managing multiple reconstitutions and schedules
GLP-1 medications like Ozempic and Wegovy are powerful tools, but over time, your body can become used to a particular dose